About EmeraMed
EmeraMed is a Healthcare company based in Dublin (Ireland) founded in 2007. Therapeutics for mercury toxicity treatment are developed by EmeraMed. EmeraMed has raised $3.86 million across 4 funding rounds from investors including European Union and EIC Fund. EmeraMed has completed 1 acquisition, including CTI Science. EmeraMed offers products and services including Emeramide. Its focus areas include Life Sciences, Toxicology, Drugs and Metal Toxicity. Its legal entity is EmeraMed Ltd.
Company details
EmeraMed was founded in 2007 in Dublin, Ireland, within the biotechnology sector. Therapeutics targeting mercury toxicity are being developed, including the metal chelator and antioxidant Irminix (Emeramide). Phase 2a trials were completed by January 23, 2016, with results expected. Marketing authorization is being pursued in the EU and US for mercury toxicity treatment. Approval for Irminix has been granted by the European Medicines Agency.
- Headquarters Dublin, Ireland
- SectorsHealthcare
- Website emeramed.com
- Social LinkedIn X Facebook YouTube
- Legal Name Emeramed Ltd
- Total Equity Funding$3.86M (USD)
in 4 rounds
- Latest Funding Round$54.29K (USD), Grant
Apr 2020
- InvestorsEuropean Union
& 1 more
- Investments & Acquisitions
Products & Services of EmeraMed
EmeraMed offers a comprehensive portfolio of products and services, including Emeramide.
Drug that chelates heavy metals and reduces oxidative stress in the body.
Apps and channels of EmeraMed
its YouTube channel EmeraMed has 291 subscribers and 2 videos.
Videos from EmeraMed
The most watched videos on EmeraMed's YouTube channel, EmeraMed (291 subscribers). Click a video to play it here.
More on EmeraMed.
Funding Insights of EmeraMed
EmeraMed has successfully raised a total of $3.86M across 4 strategic funding rounds. The most recent funding activity was a Grant round of $54.29 thousand completed in April 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $3.86M
- Total Rounds 4
- Last Round Grant — $54,286
- First Round $3.59M
(Jun 2016)
- Investors Count 2
All 4 funding rounds of EmeraMed with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2020 | $54,286 | Grant | – | – | |
| Jun 2019 | $55,992 | Grant | – | – | |
| Nov 2016 | $274,217 | Series A | – | – | – |
| Jun 2016 | $3.59M | Series A | – | – | – |
2 investors in total: 2 institutional.
Investors in EmeraMed
EmeraMed has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include European Union and EIC Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government agency and accelerator focusing on innovative startups and SMEs | eicfund.eu | Brussels, Belgium | ||
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium |
Investor details for EmeraMed
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of EmeraMed
1 people are tracked at EmeraMed (1 in leadership).
| Name | Role | Group |
|---|---|---|
Boyd Haley | Chief Scientist & CEO | Leadership |
Complete people profiles for EmeraMed
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by EmeraMed
EmeraMed has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include CTI Science.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Focused on the development of therapeutics for the treatment of drug toxicity | ctiscience.com | Lexington, United States | 2007 | Jul 2014 | •••• |
Complete acquisition details for EmeraMed
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of EmeraMed
4 dated milestones of EmeraMed across 13 years, from founding to its latest funding, stage changes and deals.
- Founded EmeraMed is founded.
- Acquisition Acquires CTI Science.
- Funding First funding round of $3.6M.
- Funding Latest funding round, Grant, of $54K.
Web traffic of EmeraMed
The website of EmeraMed (emeramed.com) receives about 2K visits a month.
- Monthly visits2K
▲ 60.2% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about EmeraMed
EmeraMed was founded in 2007 and raised its 1st funding round 9 years after it was founded.
EmeraMed is headquartered in Dublin, Ireland.
EmeraMed is a funded company, having raised a total of $3.86M across 4 funding rounds to date. The company's 1st funding round was a Series A of $3.59M, raised on Jun 2016.
EmeraMed was founded in 2007 in Dublin, Ireland, within the biotechnology sector. Therapeutics targeting mercury toxicity are being developed, including the metal chelator and antioxidant Irminix (Emeramide). Phase 2a trials were completed by January 23, 2016, with results expected. Marketing authorization is being pursued in the EU and US for mercury toxicity treatment. Approval for Irminix has been granted by the European Medicines Agency.
EmeraMed offers Emeramide.
EmeraMed has made 1 acquisition, including CTI Science.
EmeraMed has 2 investors. Key investors include European Union, and EIC Fund.
EmeraMed operates through Emeramed Ltd.